Pure Global
NCT06247280

Korean Registry of Non-Small Cell Lung Cancer Patients With EGFR Mutation

Multicenter Prospective and Retrospective Cohort Study in Non-small Cell Lung Cancer Patients With EGFR Mutation: Korean EGFR Registry
Yuhan Corporation·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Study type
Observational
Sponsor & location
Primary sponsor
Yuhan Corporation
Location
Chilgok,Wonju,Chuncheon,Bucheon-si,Uijeongbu,Bucheon,Iksan,Busan,Busan,Busan,Busan,Busan,Changwon,Daegu,Daegu,Daegu,Daejeon,Daejeon,Hwasun,Incheon,Incheon,Pusan,Seoul,Seoul,Seoul,Seoul,Seoul,Seoul,Seo, South Korea
Timeline & enrollment
Phase
N/A
Start date
Jun 24, 2022
End date
Dec 31, 2026
Enrollment
2000 participants
Primary outcome

Clinical characteristics of NSCLC patients with EGFR mutation,Clinical outcome of NSCLS patients with EGFR mutation,PFS,DFS

Summary

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and
 analyze the patient's clinical features, diagnosis, and treatment results.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06247280
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06247280 through Pure Global AI's free database. This phase not specified trial is sponsored by Yuhan Corporation and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.